Interventional Therapies for Secondary and Essential Hypertension, 1st ed. 2016 Updates in Hypertension and Cardiovascular Protection Series

This book aims to describe the role of interventional therapies in various forms of secondary hypertension and to explain the ability of such approaches to address unmet needs in the setting of uncontrolled essential hypertension. The coverage encompasses interventions in the full range of relevant conditions, including the various specific pathologies responsible for secondary hypertension, such as renal artery stenosis, coarctation of the aorta, and adrenal tumors. In each case, up-to-date information is presented on indications, procedural aspects, and patient follow-up. A further focus is the most recent knowledge on the use of invasive neuromodulation, such as renal sympathetic denervation and baroreflex stimulation. The text is supplemented by helpful explanatory diagrams and treatment algorithms. A comprehensive clinical guide of this nature has to date been absent from the literature. The book will be of interest to clinicians managing hypertensive patients, researchers investigating advanced hypertension management, and students on cardiovascular courses.

Part I Interventions for secondary hypertension - 1 Renovascular hypertension (Indications for intervention, Procedural aspects, Patient follow-up).-  2 Primary hyperaldosteronism (Diagnosis and method of localization, Management algorithm and the role of interventional therapy, Outcome and follow-up).- 3 Pheochromocytoma/paragangliomas (Confirmation of diagnosis, Preoperative management and surgical procedure, Follow-up: drugs, monitoring and other testing).- 4 Coarctation of the aorta (Indications for intervention, Stenting versus surgical repair).- Part II Adjunctive therapies - 5 Bariatric surgery ( Indications, Procedure types: safety and efficacy).- 6 Sleep apnea (Pathophysiological aspects between sleep apnea and hypertension, Indications for screening, diagnosis and treatment, Positive airway pressure and other devices).- Part III Interventions for  Essential hypertension - 7 Rationale for interventions (The cerebrovascular impact of uncontrolled hypertension,The impact of uncontrolled hypertension on the heart, What to pay attention to before interventional therapy, Optimization of antihypertensive treatment, Blood pressure measurement before and after intervention, Adherence to medications, New pharmacological agents).- 8 Renal Sympathetic Denervation (Pathophysiology, Procedural aspects, Safety, Efficacy on blood pressure, Effects beyond blood pressure lowering , Effects on sympathetic nervous system activity, Alternative methods for renal denervation).- 9 Carotid baroreceptor stimulation (Pathophysiology, Procedural aspects, Safety and efficacy: overview).- 10. Other interventions (Arteriovenous anastomosis, Carotid body modulation).- 11 Heart Failure: Interventions for neuromodulation (Rationale, Current methods. A critical overview).

Costas Tsioufis is Associate Professor of Cardiology in the 1st University Cardiology Clinic, Hippokration Hospital, Athens, Greece and Head of the Hypertension Unit of the same institute. He is currently secretary of the European Society of Hypertension and president elect of the Hellenic Cardiological Society. Professor Tsioufis research interests include hypertensive target organ damage with specific interest in microalbuminuria and renal dysfunction, left ventricular hypertrophy and arterial stiffness.  He has a special interest in the novel interventional therapies of hypertension and he is involved in major clinical trials regarding renal sympathetic denervation. In the field on Interventional Cardiology, his research has been focused on the assessment of coronary blood flow reserve and the pathophysiology of the vulnerable atherosclerotic plaque.

Roland Schmieder is a Professor of Internal Medicine, Nephrology and Hypertension, Head of the Clinical Research Centre of the Department of Nephrology and Hypertension at the University Hospital Erlangen, Germany. He also directs the Institute of Preventative Medicine at the University Erlangen-Nürnberg and the Community Hospital Nürnberg. He has served as council member and vice president of the European Society of Hypertension and is currently a member of the Council of the International Society of Hypertension. Professor Schmieder has extensive experience in the execution of human clinical trials and his research interests include nephrology, hypertension, diabetes, non-invasive cardiology and vascular medicine. He is an advisor and steering board member of several European and international multicenter studies.

Giuseppe Mancia is Professor Emeritus of the University of Milano-Bicocca and served as Professor of Medicine and Head of First Division of Medicine at the San Gerardo Hospital, Italy. He is executive officer of the European Society of Hypertension and Chair of the ESH E